McKnight began her career in Washington, D.C., and focuses her national practice on advising companies on Food and Drug Administration regulatory and compliance matters. She guides companies on regulatory aspects related to bringing new products to market – including clinical trials and the collection, sharing and use of patient and product information – and maintaining compliant operations in the areas of manufacturing, distribution, and promotion and advertising. She is especially attuned to the compliance needs of clients navigating the late stages of clinical development and making the transition to their first commercial launch.
“Becca has extensive experience and a keen understanding of issues related to traditional health care and pharmaceutical sectors and the convergence with technology,” said Scot Hasselman, co-chair of Reed Smith’s Life Sciences Health Industry Group. “She bolsters our FDA regulatory capabilities at a time when companies are facing evolving challenges related to compliance and enforcement. We’re thrilled that she has decided to join the team.”
McKnight also assists clients with developing FDA and health care compliance policies and procedures, and conducting risk assessments and compliance investigations. Reed Smith’s stellar reputation in the health care and life sciences sectors and commitment to diversity, mental health and positive firm culture were among the reasons she decided to make the move.